GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory syncytial virus jab Arexvy, sending the pharmaceutical group’s shares down more than 3 per cent ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance ... saw sales tumble 72%, its influenza vaccine saw sales slump 24% and its shingles vaccine saw sales weaken by 7%.

(Reuters) -GSK (GSK) on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...

Notably, GSK points to the rapid creation of an mRNA vaccine candidate during the 2013 influenza outbreak in China, setting a record for vaccine development time. The scientific journal Nature hig ...

Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from ...

British drugmaker GSK on Wednesday bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials and extending the German ...

British Drugmaker GSK Moves MRNA Flu Vaccine to Late-stage Trials British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme ...

and inactivated trivalent influenza vaccine (TIV; Fluarix™, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to ...

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

I'm pleased to report that despite some challenges, this has been a positive quarter for GSK, and we're delivering ... headline data from our mRNA influenza vaccine candidate, demonstrating ...